How Would You Manage This Patient With Obesity? Grand Rounds Discussion From Beth Israel Deaconess Medical Center
The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Abstract
In 2022, 1 in 8 people in the world were living with obesity, and lifestyle interventions that include diet, exercise, and behavioral modification have been the foundation for management of obesity. Recently, pharmacologic therapies have been developed for management of obesity, the newest of these being glucagon-like peptide 1 receptor agonists. With the development of new pharmacologic options, the American Gastroenterological Association developed a guideline in 2022 to provide evidence-based recommendations for the pharmacologic management of obesity in adults and recommended, for adults with obesity or overweight with weight-related complications who have had an inadequate response to lifestyle interventions, adding pharmacologic agents to lifestyle interventions over continuing lifestyle interventions alone. In this article, 2 experts review the available evidence to answer the following questions: How effective are lifestyle interventions for the treatment of obesity? How effective are pharmacologic interventions for the treatment of obesity? Given these options, how do you engage in a shared decision-making discussion to develop a mutually agreed-on treatment plan?
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“This combined strategy leverages the benefits of medication and surgery alongside personalized lifestyle interventions to achieve superior health outcomes [323,324].”
From Lifestyle Medicine for Obesity in the Era of Highly Effective Anti-Obesity Treatment (2025) · cites this paper as [323]
Citations
Cites
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205
Tirzepatide Once Weekly for the Treatment of Obesity
Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2206038 · Cited by 3,838 · cited 1×
“Recently FDA-approved tirzepa-tide has dual-hormone agonistic activity at the GLP-1 receptor and the glucose-dependent insulinotropic polypeptide receptor (GIP/GLP-1RA) and produces weight loss up to 20% at the highest dose (10 mg subcutaneously) (19, 20).”
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., Deanfield, J., Emerson, S. S., Esbjerg, S., Hardt-Lindberg, S., Hovingh, G. K., Kahn, S. E., Kushner, R. F., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2307563 · Cited by 3,236 · cited 3×
“…of organs affected and modes of action may explain the extent of bene fi ts found beyond management of obesity, including treatment of metabolic dysfunction – associated stea-totic liver disease (MASLD; formerly called nonalcoholic fatty liver disease) and improvement in cardiovascular outcomes (5).”
Thompson, P. D., Buchner, D., Piña, I. L., Balady, G. J., Williams, M. A., Marcus, B. H., Berra, K., Blair, S. N., Costa, F., Franklin, B., et al. (2003) · Circulation · doi:10.1161/01.cir.0000075572.40158.77 · Cited by 2,132
Glucagon-like peptide 1 (GLP-1)
Müller, T. D., Finan, B., Bloom, S. R., D'Alessio, D., Drucker, D. J., Flatt, P. R., Fritsche, A., Gribble, F., Grill, H. J., Habener, J. F., et al. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.09.010 · Cited by 1,868 · cited 1×
“The GLP-1RAs have various metabolic effects, including glucose-dependent stimulation of insulin secretion, delayed gastric emptying, and inhibition of food intake (4).”
Wing, R. R., Lang, W., Wadden, T. A., Safford, M., Knowler, W. C., Bertoni, A. G., Hill, J. O., Brancati, F. L., Peters, A., Wagenknecht, L., et al. (2011) · Diabetes Care · doi:10.2337/dc10-2415 · Cited by 1,828
Rubino, D., Abrahamsson, N., Davies, M., Hesse, D., Greenway, F. L., Jensen, C., Lingvay, I., Mosenzon, O., Rosenstock, J., Rubio, M. A., et al. (2021) · JAMA · doi:10.1001/jama.2021.3224 · Cited by 1,444
Effect of weight loss with lifestyle intervention on risk of diabetes
Hamman, R. F., Wing, R. R., Edelstein, S. L., Lachin, J. M., Bray, G. A., Delahanty, L., Hoskin, M., Kriska, A. M., Mayer-Davis, E. J., Pi-Sunyer, X., et al. (2006) · Diabetes Care · doi:10.2337/dc06-0560 · Cited by 1,344
Messier, S. P., Loeser, R. F., Miller, G. D., Morgan, T. M., Rejeski, W. J., Sevick, M. A., Ettinger, W. H., Pahor, M., & Williamson, J. D. (2004) · Arthritis & Rheumatism · doi:10.1002/art.20256 · Cited by 1,065 · cited 1×
“Additional health bene fi ts included improvements in obstructive sleep apnea (9), knee osteoarthritis (10, 11), MASLD (12), quality of life, and depression (13).”
Cited by
Lifestyle Medicine for Obesity in the Era of Highly Effective Anti-Obesity Treatment
Sannidhi, D., Abeles, R., Andrew, W., Bonnet, J. P., Vitale, K., Niranjan, V., Gulati, M., Pauly, K., Moran, R., Alexander, L., et al. (2025) · Nutrients · doi:10.3390/nu17142382 · Cited by 29
“This combined strategy leverages the benefits of medication and surgery alongside personalized lifestyle interventions to achieve superior health outcomes [323,324].”
Wee, C. C., Arbaje, A. I., Bering, H., Blount, L. G., Joseph, J. J., Kahan, S. I., Apovian, C. M., & White-Faines, A. (2025) · Annals of Internal Medicine · doi:10.7326/annals-25-00675 · Cited by 3
Metadata
- Authors
- Burns, R. B., Jay, M. R., Thorndike, A. N., & Kanjee, Z.
- Affiliations
- Beth Israel Deaconess Medical Center (US)
- New York University (US)
- Harvard University (US)
- Venue
- Annals of Internal Medicine
- Publisher
- American College of Physicians
- Published
- 2024-10
- Volume
- 177
- Issue
- 10
- Pages
- 1415-1424
- ISSN
- 0003-4819 (ISSN-L)
- 1539-3704
- OpenAlex
- W4403177428
- Cited by
- 2
- References
- 49
- Citations by year
- 2025: 2
- FWCI
- 0.57
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.acpjournals.org/journal/aim/text-and-data-mining (tdm)
- Locations
- Annals of Internal Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Surgery › Bariatric Surgery and Outcomes
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Obesity, Physical Activity, Diet
- Keywords
- obesity, obesity pharmacotherapy, lifestyle intervention, GLP-1 receptor agonists, shared decision-making, treatment effectiveness, American Gastroenterological Association guidelines
- MeSH terms
- Decision Making, Shared, Adult, Humans, Life Style, Obesity, Anti-Obesity Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: How Would You Manage This Patient With Obesity? Grand Rounds Discussion From Beth Israel Deaconess Medical Center. https://app.cochat.ai/papers/10.7326/annals-24-01740
- The paper
- Burns, R. B., Jay, M. R., Thorndike, A. N., & Kanjee, Z. (2024). How Would You Manage This Patient With Obesity? Grand Rounds Discussion From Beth Israel Deaconess Medical Center. Annals of Internal Medicine. https://doi.org/10.7326/annals-24-01740
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.